Dopamine receptor (non-ergoline agonist) drugs for Parkinson's Disease
3 tracked Dopamine receptor (non-ergoline agonist) drugs in the Parkinson's Disease race. The class explanation lives on the Dopamine receptor (non-ergoline agonist) page; the full indication pipeline across every mechanism is on the Parkinson's Disease page.
2 approved / phase 41 Phase 1
Head-to-head evidence: Apomorphine (Apokyn) vs Apomorphine (Onapgo) · Apomorphine (Apokyn) vs SER-252 (PEOZ-apomorphine) · Apomorphine (Onapgo) vs SER-252 (PEOZ-apomorphine)